Skip to main content
. 2021 Nov 17;8:744788. doi: 10.3389/fcvm.2021.744788

Figure 5.

Figure 5

The economic burden of angina in women with suspected ischemic heart disease. Estimated lifetime costs (including sensitivity analyses ranges) of pharmacologic therapy and hospitalization for cardiovascular disease in women with non-obstructive and 1-vessel to 3-vessel CAD. Reprinted with permission (103).